Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus. Redondo A, Barretina P, Pérez-Fidalgo A, Rubio MJ, González-Martín A. Journal of Gynecologic Oncology. 2023 Sep;34(5):e57. doi: 10.3802/jgo.2023.34.e57. PMID: 37116953

Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1. Escudero Vilaplana V, Collado Borrell R, De Castro J, Insa A, Martinez A, Fernandez E, Sullivan I, Flores A, Arrabal N, Carcedo D, Manzaneque A. Journal of Medical Economics. 2023 Jan-Dec;26(1):445-453. doi: 10.1080/13696998.2023.2188844. PMID: 36883193

Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology+MIR section. Martinez D, Quilez-Cutillas A, Jimenez-Labaig P, Sesma A, Tarazona N, Pacheco-Barcia V, Obispo B, Paez D, Quintanar T, Sanchez-Canovas M, Montes A, Felip E, Rodriguez-Lescure A, Elez E. Clinical & translational oncology. 2023 Mar;25(3):796-802. doi: 10.1007/s12094-022-02989-3. PMID: 36418642

Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: a Delphi consensus study in Europe. Kroese T, van Laarhoven H, Schoppman S, Deseyne P, van Cutsem E, Haustermans K, Nafteux P, Thomas M, Obermannova R, Mortensen H, Nordsmark M, Pfeiffer P, Elme A, Adenis A, Piessen G, Bruns C, Lordick F, Gockel I, Moehler M, Gani C, Liakakos T, Reynolds J, Morganti A, Rosati R, Castoro C, Cellini F, D’Ugo D, Roviello F, Bencivenga M, de Manzoni G, van Berge Henegouwen M, Hulshof M, van Dieren J, Vollebergh M, van Sandick J, Jeene P, Muijs C, Slingerland M, Voncken F, Hartgrink H, Creemers G, van der Sangen M, Nieuwenhuijzen G, Berbee M, Verheij M, Wijnhoven B, Beerepoot L, Mohammad N, Mook S, Ruurda J, Kolodziejczyk P, Polkowski W, Wyrwicz L, Alsina M, Pera M, Kanonnikoff T, Cervantes A, Nilsson M, Monig S, Wagner A, Guckenberger M, Griffiths E, Smyth E, Hanna G, Markar S, Chaudry M, Hawkins M, Cheong E, van Hillegersberg R, van Rossum P. European Journal of Cancer. 2023 Feb 24;185:28-39. doi: 10.1016/j.ejca.2023.02.015. PMID: 36947929

Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR-MASH score. Marti-Aguado D, Arnouk J, Liang J, Lara-Romero C, Behari J, Furlan A, Jimenez-Pastor A, Ten-Esteve A, Alfaro-Cervello C, Bauza M, Gallen-Peris A, Gimeno-Torres M, Merino-Murgui V, Perez-Girbes A, Benlloch S, Perez-Rojas J, Puglia V, Ferrández-Izquierdo A, Aguilera V, Giesteira B, França M, Monton C, Escudero-García D, Alberich-Bayarri A, Serra M, Bataller R, Romero-Gomez M, Marti-Bonmati L. Liver International. 2023 Oct 30. doi: 10.1111/liv.15766. PMID: 37904633

Diagnostic algorithm to subclassify atypical spitzoid tumors in low and high risk according to their methylation status. González-Muñoz J, Sánchez-Sendra B, Monteagudo C. International Journal of Molecular Sciences. 2023 Dec 25;25(1):318. doi: 10.3390/ijms25010318. PMID: 38203489

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Desai J, Alonso G, Kim SH, Cervantes A, Karasic T, Medina L, Shacham-Shmueli E, Cosman R, Falcon A, Gort E, Guren T, Massarelli E, Miller WH Jr, Paz-Ares L, Prenen H, Amatu A, Cremolini C, Kim TW, Moreno V, Ou SI, Passardi A, Sacher A, Santoro A, Stec R, Ulahannan S, Arbour K, Lorusso P, Luo J, Patel MR, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Jun T, Dharia NV, Schutzman JL; GO42144 Investigator and Study Group; Han SW. Nature Medicine. 2023 Dec 5. doi: 10.1038/s41591-023-02696-8. PMID: 38052910

Does month of birth influence colorectal cancer prognosis?. Martín-Arévalo J, Moro-Valdezate D, Pla-Martí V, García-Botello S, Moya-Marcos P, Izquierdo-Moreno A, Pérez-Santiago L, Casado-Rodrigo D, Rosello-Keränen S, Espí-Macías A. Langenbecks Archives of Surgery. 2023 Oct 26;408(1):419. doi: 10.1007/s00423-023-03161-3. PMID: 37882968

Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain. De Castro J, Insa A, Collado-Borrell R, Escudero-Vilaplana V, Martinez A, Fernandez E, Sullivan I, Arrabal N, Carcedo D, Manzaneque A. BMC Pulmonary Medicine. 2023 Feb 21;23(1):69. doi: 10.1186/s12890-023-02356-0. PMID: 36809990

Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: phase 2 study results. Ciardiello F, Bang Y, Cervantes A, Dvorkin M, Lopez C, Metges J, Ruiz A, Calvo M, Strickland A, Kannourakis G, Muro K, Kawakami H, Wei J, Borg C, Zhu Z, Gupta N, Pelham R, Shen L. Cancer Medicine. 2023 Jun;12(12):13145-13154. doi: 10.1002/cam4.5997. PMID: 37260158

Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon D, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y. Lancet Oncology. 2023 Aug;24(8):925-935. doi: 10.1016/S1470-2045(23)00275-9. PMID: 37541273

European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer. Martinelli E, Arnold D, Cervantes A, Stintzing S, Van Cutsem E, Tabernero J, Taieb J, Wasan H, Ciardiello F. Cancer Treatment Reviews. 2023 Apr;115:102541. doi: 10.1016/j.ctrv.2023.102541. PMID: 36931147

Evaluation of results after 112 radioembolizations with 90Y-microspheres. Casans-Tormo I, Guijarro-Rosaleny J, Lluch-Garcia P, Rodriguez-Parra H, Rosello-Keranen S, Asensio-Valero L. Revista Espanola de Medicina Nuclear e Imagen Molecular. 2023 Jul-Aug;42(4):255-264. doi: 10.1016/j.remnie.2023.05.004. PMID: 37269983

First-Line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC. Zhou C, Solomon B, Loong H, Park K, Perol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak M, Santini F, Elamin Y, Drilon A, Wolf J, Payakachat N, Uh M, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin A, Lin B, Goto K. New England Journal of Medicine. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457. PMID: 37870973

FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer. Cervantes A, Prager GW. ESMO Open. 2023 Feb 20;8(2):100883. doi: 10.1016/j.esmoop.2023.100883. PMID: 36812740

Hernández J,Chow CY,Chatras H,França PDD,Samuels ZV,Cornejo M,King GF,Lewis JS,Reiner T,Gonzales J. Development and Validation of Nerve-Targeted Bacteriochlorin Sensors. J. Am. Chem. Soc. 2023. 145. (26):p. 14276-14287. IF:14,400. (1).

How organoids can improve personalized treatment in patients with gastro-esophageal tumors. Cabeza-Segura M, Garcia-Micò B, La Noce M, Nicoletti GF, Conti V, Filippelli A, Fleitas T, Cervantes A, Castillo J, Papaccio F. Current Opinion in Pharmacology. 2023 Feb 23;69:102348. doi: 10.1016/j.coph.2023.102348. PMID: 36842387

In the Literature: january 2023. Martin-Arana J, Gambardella V, Tarazona N, Cejalvo JM, Cervantes A. ESMO Open. 2023 Jan 3;8(1):100763. doi: 10.1016/j.esmoop.2022.100763. PMID: 36603523

In the literature: July 2023. Gambardella V, Gimeno-Valiente F, Roselló S, Cervantes A. ESMO Open. 2023 Aug;8(4):101612. doi: 10.1016/j.esmoop.2023.101612. PMID: 37467659

In the Literature: March 2023. Gambardella V, Tarazona N, Roda D, Cervantes A. ESMO Open. 2023 Apr;8(2):101203. doi: 10.1016/j.esmoop.2023.101203. PMID: 37018871

In the literature: May 2023. Gambardella V, Cejalvo J, Cervantes A. ESMO Open. 2023 May 15;8(3):101562. doi: 10.1016/j.esmoop.2023.101562. PMID: 37196398

In the literature: September 2023. Lamarca A, Moreno V, Gambardella V, Cervantes A. ESMO Open. 2023 Oct 16;8(6):102032. doi: 10.1016/j.esmoop.2023.102032. PMID: 37852035

Lenvatinib plus pembrolizumab a new effective combination of targeted agents. Perez-Fidalgo J, Martinelli E. ESMO Open. 2023 Feb 28;8(2):101157. doi: 10.1016/j.esmoop.2023.101157. PMID: 36863093

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Journal of Clinical Oncology. 2023 Nov 20;41(33):5080-5089. doi: 10.1200/JCO.22.02773. PMID: 37967516

Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared to long-course chemoradiotherapy and surgery – a five-year follow-up of the RAPIDO Trial. Dijkstra EA, Nilsson PJ, Hospers GAP, Bahadoer RR, Meershoek-Klein Kranenbarg E, Roodvoets AGH, Putter H, Berglund A, Cervantes A, Crolla RMPH, Hendriks MP, Capdevila J, Edhemovic I, Marijnen CAM, van de Velde CJH, Glimelius B, van Etten B. Annals of Surgery. 2023 Oct 1;278(4):e766-e772. doi: 10.1097/SLA.0000000000005799. PMID: 36661037

Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy. Linares J, Sallent-Aragay A, Badia-Ramentol J, Recort-Bascuas A, Mendez A, Manero-Ruperez N, Re DL, Rivas EI, Guiu M, Zwick M, Iglesias M, Martinez-Ciarpaglini C, Tarazona N, Varese M, Hernando-Momblona X, Canellas-Socias A, Orrillo M, Garrido M, Saoudi N, Elez E, Navarro P, Tabernero J, Gomis RR, Batlle E, Pisonero J, Cervantes A, Montagut C, Calon A. Nature Communications. 2023 Feb 10;14(1):746. doi: 10.1038/s41467-023-36334-1. PMID: 36765091

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J, Seligmann J, De Baere T, Osterlund P, Yoshino T, Martinelli E. Annals of Oncology. 2023 Jan;34(1):10-32. doi: 10.1016/j.annonc.2022.10.003. PMID: 36307056

Napabucasin plus FOLFIRI in patients with previously treated metastatic colorectal cancer: results from the open-label, randomized phase III CanStem303C Study. Shah M, Yoshino T, Tebbutt N, Grothey A, Tabernero J, Xu R, Cervantes A, Oh S, Yamaguchi K, Fakih M, Falcone A, Wu C, Chiu V, Tomasek J, Bendell J, Fontaine M, Hitron M, Xu B, Taieb J, Van Cutsem E. Clinical Colorectal Cancer. 2022 Nov 11:S1533-0028(22)00125-6. doi: 10.1016/j.clcc.2022.11.002. PMID: 36503738

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Jhaveri K, Eli L, Wildiers H, Hurvitz S, Guerrero-Zotano A, Unni N, Brufsky A, Park H, Waisman J, Yang E, Spanggaard I, Reid S, Burkard M, Vinayak S, Prat A, Arnedos M, Bidard F, Loi S, Crown J, Bhave M, Piha-Paul S, Suga J, Chia S, Saura C, Garcia-Saenz J, Gambardella V, de Miguel M, Gal-Yam E, Rapael A, Stemmer S, Ma C, Hanker A, Ye D, Goldman J, Bose R, Peterson L, Bell J, Frazier A, DiPrimeo D, Wong A, Arteaga C, Solit D. Annals of Oncology. 2023 Oct;34(10):885-898. doi: 10.1016/j.annonc.2023.08.003. PMID: 37597578

Oral selinexor as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer. Vergote I, Perez-Fidalgo J, Hamilton E, Valabrega G, Gorp T, Sehouli J, Cibula D, Levy T, Welch S, Richardson D, Guerra E, Scambia G, Henry S, Wimberger P, Miller D, Klat J, Martinez-Garcia J, Raspagliesi F, Pothuri B, Romero I, Bergamini A, Slomovitz B, Schochter F, Hogdall E, Farinas-Madrid L, Monk B, Michel D, Kauffman M, Shacham S, Mirza M, Makker V. Journal of Clinical Oncology. 2023 Dec 10;41(35):5400-5410. doi: 10.1200/JCO.22.02906. PMID: 37669480

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial. Friedlander M, Mileshkin L, Lombard J, Frentzas S, Gao B, Wilson M, Meniawy T, Baron-Hay S, Briscoe K, McCarthy N, Fountzilas C, Cervantes A, Ge R, Wu J, Spira A. British Journal of Cancer. 2023 Sep;129(5):797-810. doi: 10.1038/s41416-023-02349-0. PMID: 37474720

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer. Yoshino T, Cervantes A, Bando H, Martinelli E, Oki E, Xu R, Mulansari N, Govind Babu K, Lee M, Tan C, Cornelio G, Chong D, Chen L, Tanasanvimon S, Prasongsook N, Yeh K, Chua C, Sacdalan M, Sow Jenson W, Kim S, Chacko R, Syaiful R, Zhang S, Curigliano G, Mishima S, Nakamura Y, Ebi H, Sunakawa Y, Takahashi M, Baba E, Peters S, Ishioka C, Pentheroudakis G. ESMO Open. 2023 May 24;8(3):101558. doi: 10.1016/j.esmoop.2023.101558. PMID: 37236086

Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer. Provencio M, Nadal E, Gonzalez-Larriba J, Martinez-Marti A, Bernabe R, Bosch-Barrera J, Casal-Rubio J, Calvo V, Insa A, Ponce S, Reguart N, de Castro J, Mosquera J, Cobo M, Aguilar A, Lopez Vivanco G, Camps C, Lopez-Castro R, Moran T, Barneto I, Rodriguez-Abreu D, Serna-Blasco R, Benitez R, Aguado de la Rosa C, Palmero R, Hernando-Trancho F, Martin-Lopez J, Cruz-Bermudez A, Massuti B, Romero A. New England Journal of Medicine. 2023 Aug 10;389(6):504-513. doi: 10.1056/NEJMoa2215530. PMID: 37379158

Pharmacokinetics (PK) of Tiragolumab in first-in-human study in patients with mixed solid tumors (GO30103). Garralda E, Oh D, Italiano A, Bedard P, Delord J, Calvo E, LoRusso P, Wainberg Z, Cervantes A, Rodriguez-Vida A, Shemesh C, Sane R, Mendus D, Ding H, Hendricks R, Meng R, Cho B, Kim T, Wu B. Journal of Clinical Pharmacology. 2023 Dec 17. doi: 10.1002/jcph.2397. PMID: 38105505

Phase 1 study of Elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, as monotherapy or combined with chemotherapy in patients with advanced malignancies. Carneiro B, Cavalcante L, Mahalingam D, Saeed A, Safran H, Ma W, Coveler A, Powell S, Bastos B, Davis E, Sahai V, Mikrut W, Longstreth J, Smith S, Weiskittel T, Li H, Borden B, Harvey R, Sahebjam S, Cervantes A, Koukol A, Mazar A, Steeghs N, Kurzrock R, Giles F, Munster P. Clinical Cancer Research. 2023 Nov 20. doi: 10.1158/1078-0432.CCR-23-1916. PMID: 37982822

Phase Ia/b Study of giredestrant ±palbociclib and ±luteinizing hormone-releasing hormone agonists in estrogen receptor-positive, HER2-negative, locally advanced/metastatic breast cancer. Jhaveri KL, Bellet-Ezquerra M, Turner NC, Loi S, Bardia A, Boni V, Sohn J, Neilan TG, Villanueva-Vázquez R, Kabos P, García Estévez L, Lopez-Miranda E, Perez Fidalgo JA, Perez-Garcia JM, Yu J, Fredrickson J, Moore HM, Chang CW, Bond JW, Eng-Wong J, Gates MR, Lim E. Clinical Cancer Research. 2023 Nov 3. doi: 10.1158/1078-0432.CCR-23-1796. PMID: 37921755

Preoperative treatment of locally advanced rectal cancer. Sebag-Montefiore D, Cervantes A, Rodel C. New England Journal of Medicine. 2023 Oct 26;389(17):1631. doi: 10.1056/NEJMc2309857. PMID: 37888929

Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction. Papaccio F, Garcia-Mico B, Gimeno-Valiente F, Cabeza-Segura M, Gambardella V, Gutierrez-Bravo MF, Alfaro-Cervello C, Martinez-Ciarpaglini C, Rentero-Garrido P, Zuniga-Trejos S, Carbonell-Asins JA, Fleitas T, Rosello S, Huerta M, Sanchez Del Pino MM, Sabater L, Roda D, Tarazona N, Cervantes A, Castillo J. Journal of Experimental & Clinical Cancer Research. 2023 Jan 6;42(1):8. doi: 10.1186/s13046-022-02591-z. PMID: 36604765

Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. Rudin C, Cervantes A, Dowlati A, Besse B, Ma B, Costa D, Schmid P, Heist R, Villaflor V, Spahn J, Li S, Cha E, Riely G, Gettinger S. ESMO Open. 2023 Mar 3;8(2):101160. doi: 10.1016/j.esmoop.2023.101160. PMID: 36871392

SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022) (vol 25, pg 2679, 2023). Garcia-Campelo R, Sullivan I, Arriola E, Insa A, Vidal O, Cruz-Castellanos P, Moran T, Reguart N, Zugazagoitia J, Domine M. Clinical & Translational Oncology. 2023 Sep;25(9):2760-2762. doi: 10.1007/s12094-023-03290-7. PMID: 37556098

SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022). Garcia-Campelo R, Sullivan I, Arriola E, Insa A, Juan Vidal O, Cruz-Castellanos P, Moran T, Reguart N, Zugazagoitia J, Domine M. Clinical & Translational Oncology. 2023 Sep;25(9):2679-2691. doi: 10.1007/s12094-023-03216-3. PMID: 37418123

Sequencing paired tumor DNA and white blood cells improves circulating tumor DNA tracking and detects pathogenic germline variants in localized colon cancer. Gimeno-Valiente F, Martín-Arana J, Tébar-Martínez R, Gambardella V, Martínez-Ciarpaglini C, García-Micó B, Martínez-Castedo B, Palomar B, García-Bartolomé M, Seguí V, Huerta M, Moro-Valdezate D, Pla-Martí V, Pérez-Santiago L, Roselló S, Roda D, Cervantes A, Tarazona N. ESMO Open. 2023 Nov 9;8(6):102051. doi: 10.1016/j.esmoop.2023.102051. PMID: 37951129

Strategies for improving detection of circulating tumor DNA using next generation sequencing. Roberto T, Jorge M, Francisco G, Noelia T, Pilar R, Andres C. Cancer Treatment Reviews. 2023 Sep;119:102595. doi: 10.1016/j.ctrv.2023.102595. PMID: 37390697

Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: a multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer. Kroese TE, van Rossum PSN, Nilsson M, Lordick F, Smyth EC, Rosati R, Nafteux P, D’Ugo D, Chaudry MA, Polkowkski W, Roviello F, Gockel I, Kolodziejczyk P, Haustermans K, Guckenberger M, Nordsmark M, Hawkins MA, Cervantes A, Fleitas T, van Cutsem E, Moehler M, Wagner AD, van Laarhoven HWM, van Hillegersberg R. European Journal of Surgical Oncology. 2023 Jan;49(1):21-28. doi: 10.1016/j.ejso.2022.09.012. PMID: 36184420

The Helicobacter pylori Genome Project: insights into H. pylori population structure from analysis of a worldwide collection of complete genomes. Thorell K, Munoz-Ramirez Z, Wang D, Sandoval-Motta S, Boscolo Agostini R, Ghirotto S, Torres R, Falush D, Camargo M, Rabkin C. Nature Communications. 2023 Dec 11;14(1):8184. doi: 10.1038/s41467-023-43562-y. PMID: 38081806

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022. Ducreux M, Abou-Alfa G, Bekaii-Saab T, Berlin J, Cervantes A, de Baere T, Eng C, Galle P, Gill S, Gruenberger T, Haustermans K, Lamarca A, Laurent-Puig P, Llovet J, Lordick F, Macarulla T, Mukherji D, Muro K, Obermannova R, O’Connor J, O’Reilly E, Osterlund P, Philip P, Prager G, Ruiz-Garcia E, Sangro B, Seufferlein T, Tabernero J, Verslype C, Wasan H, Van Cutsem E. ESMO Open. 2023 May 30;8(3):101567. doi: 10.1016/j.esmoop.2023.101567. PMID: 37263081

The percentage of mesorectal infiltration as a prognostic factor after curative surgery for pT3 rectal cancer. Sancho-Muriel J, Giner F, Cholewa H, Garcia-Granero A, Roselló S, Flor-Lorente B, Cervantes A, Garcia-Granero E, Frasson M. Colorectal Disease. 2023 Jun;25(6):1135-1143. doi: 10.1111/codi.16522. PMID: 36790134

The prognostic potential of CDX2 in colorectal cancer: harmonizing biology and clinical practice. Badia-Ramentol J, Gimeno-Valiente F, Duréndez E, Martínez-Ciarpaglini C, Linares J, Iglesias M, Cervantes A, Calon A, Tarazona N. Cancer Treatment Reviews. 2023 Dec:121:102643. doi: 10.1016/j.ctrv.2023.102643. PMID: 37871463

The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer-results from the RAPIDO trial. Dijkstra E, Zwart W, Nilsson P, Putter H, Roodvoets A, Meershoek-Klein Kranenbarg E, Frodin J, Nygren P, Ostergaard L, Kersten C, Verbiene I, Cervantes A, Hendriks M, Capdevila J, Edhemovic I, van de Velde C, Marijnen C, van Etten B, Hospers G, Glimelius B. ESMO Open. 2023 Mar 3;8(2):101158. doi: 10.1016/j.esmoop.2023.101158. PMID: 36871393

Timing of meals and sleep in the Mediterranean population: the effect of taste, genetics, environmental determinants, and interactions on obesity phenotypes. Barragan R, Fernandez Carrion R, Asensio Marquez EM, Ortega Azorin C, Alvarez Sala A, Perez-Fidalgo A, Sorli JV, Portoles O, Gonzalez Monje I, St-Onge MP, Corella D. Nutrients. 2023 Jan 30;15(3):708. doi: 10.3390/nu15030708. PMID: 36771415

Trisomy 12p mosaicism syndrome in a patient with hypopigmented cutaneous mosaicism and three cell lines in peripheral blood. Porcar Saura S, Diaz Gimenez M, Guillen-Climent S, Villar C, Ruiz Quilez A, Abellan Sanchez M, Cuesta Peredo A, Martin J. Journal of the European Academy of Dermatology and Venereology. 2023 Jan;37(1):e54-e58. doi: 10.1111/jdv.18555. PMID: 35993792

Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO Metastatic Colorectal Cancer Living Guideline. Cervantes A, Martinelli E. Annals of Oncology. 2023 Nov 7:S0923-7534(23)04335-1. doi: 10.1016/j.annonc.2023.10.129. PMID: 37951473

Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS). Perez-Fidalgo J, Ortega E, Ponce J, Redondo A, Sevilla I, Valverde C, Verdum J, de Alava E, Lopez M, Marquina G, Sebio A. Therapeutic Advances in Medical Oncology. 2023 Mar 28;15:17588359231157645. doi: 10.1177/17588359231157645. PMID: 37007636

Ximenez E, Ruiperez A. Selective neoadjuvant therapy in locally advanced rectal cancer: Who and why?. Cirugia Espanola. 2023 May;101(5):309-311. doi: 10.1016/j.cireng.2022.11.007. PMID: 36423876

Young oncologists’ perspective on the role and future of the clinician-scientist in oncology. Lim K, Westphalen C, Berghoff A, Cardone C, Connolly E, Guven D, Kfoury M, Kocakavuk E, Mando P, Mariamidze E, Matikas A, Moutafi M, Oing C, Pihlak R, Punie K, Sanchez-Bayona R, Sobczuk P, Starzer A, Tecic Vuger A, Zhu H, Cruz-Ordinario M, Altuna S, Canario R, Vuylsteke P, Banerjee S, de Azambuja E, Cervantes A, Lambertini M, Mateo J, Amaral T. Esmo Open. 2023 Aug 31;8(5):101625. doi: 10.1016/j.esmoop.2023.101625. PMID: 37659290

Automated whole-liver MRI segmentation to assess steatosis and iron quantification in chronic liver disease. Marti-Aguado D, Jimenez-Pastor A, Alberich-Bayarri A, Rodriguez-Ortega A, Alfaro-Cervello C, Mestre-Alagarda C, Bauza M, Gallen-Peris A, Valero-Perez E, Ballester MP, Gimeno-Torres M, Perez-Girbes A, Benlloch S, Perez-Rojas J, Puglia V, Ferrandez A, Aguilera V, Escudero-Garcia D, Serra MA, Marti-Bonmati L. Radiology. 2022 Feb;302(2):345-354. doi: 10.1148/radiol.2021211027. PMID: 34783592

Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Henriksen TV, Tarazona N, Frydendahl A, Reinert T, Gimeno-Valiente F, Carbonell-Asins JA, Sharma S, Renner D, Hafez D, Roda D, Huerta M, Rosello S, Madsen AH, Love US, Andersen PV, Thorlacius-Ussing O, Iversen LH, Gotschalck KA, Sethi H, Aleshin A, Cervantes A, Andersen CL. Clinical Cancer Research. 2022 Feb 1;28(3):507-517. doi: 10.1158/1078-0432.CCR-21-2404. PMID: 34625408

Clinical management of metastatic colorectal cancer in the era of precision medicine. Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. CA-A Cancer Journal for Clinicians. 2022 Jul;72(4):372-401. doi: 10.3322/caac.21728. PMID: 35472088

Colorectal cancer survival: prevalence of psychosocial distress and unmet supportive care needs. Andreu Y, Martinez P, Soto-Rubio A, Fernandez S, Bosch C, Cervantes A. Supportive Care in Cancer. 2022 Feb;30(2):1483-1491. doi: 10.1007/s00520-021-06513-1. PMID: 34529142

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. Peters S, Pujol J, Dafni U, Domine M, Popat S, Reck M, Andrade J, Becker A, Moro-Sibilot D, Curioni-Fontecedro A, Molinier O, Nackaerts K, Insa Molla A, Gervais R, Lopez Vivanco G, Madelaine J, Mazieres J, Faehling M, Griesinger F, Majem M, Gonzalez Larriba J, Provencio Pulla M, Vervita K, Roschitzki-Voser H, Ruepp B, Mitchell P, Stahel R, Le Pechoux C, De Ruysscher D, ETOP/IFCT 4-12 STIMULI Collaborators. Annals of Oncology. 2022 Jan;33(1):67-79. doi: 10.1016/j.annonc.2021.09.011. PMID: 34562610

Corrigendum to “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology 29 suppl. 4 (2018) v238-iv255]. Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E; ESMO Guidelines Committee. Annals of Oncology. 2022 Jun;33(6):666. doi: 10.1016/j.annonc.2022.03.009. PMID: 35365377

Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. Kroese T, van Hillegersberg R, Schoppmann S, Deseyne P, Nafteux P, Obermannova R, Nordsmark M, Pfeiffer P, Hawkings M, Smyth E, Markar S, Hanna G, Cheong E, Chaudry A, Elme A, Adenis A, Piessen G, Gani C, Bruns C, Moehler M, Liakakos T, Reynolds J, Morganti A, Rosati R, Castoro C, D’Ugo D, Roviello F, Bencivenga M, de Manzoni G, Jeene P, van Sandick J, Muijs C, Slingerland M, Nieuwenhuijzen G, Wijnhoven B, Beerepoot L, Kolodziejczyk P, Polkowski W, Alsina M, Pera M, Kanonnikoff T, Nilsson M, Guckenberger M, Monig S, Wagner D, Wyrwicz L, Berbee M, Gockel I, Lordick F, Griffiths E, Verheij M, van Rossum P, van Laarhoven H, OMEC working group. European Journal of Cancer. 2022 Feb 5;164:18-29. doi: 10.1016/j.ejca.2021.11.032. PMID: 35134666

Efficacy of niraparib by time of surgery and postoperative residual disease status: a post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. O’Cearbhaill R, Perez-Fidalgo J, Monk B, Tusquets I, McCormick C, Fuentes J, Moore R, Vulsteke C, Shahin M, Forget F, Bradley W, Hietanen S, O’Malley D, Dorum A, Slomovitz B, Baumann K, Selle F, Calvert P, Artioli G, Levy T, Kumar A, Malinowska I, Li Y, Gupta D, Gonzalez-Martin A. Gynecologic Oncology. 2022 Jul;166(1):36-43. doi: 10.1016/j.ygyno.2022.04.012. PMID: 35550709

ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe. Vaz-Luis I, Masiero M, Cavaletti G, Cervantes A, Chlebowski R, Curigliano G, Felip E, Ferreira A, Ganz P, Hegarty J, Jeon J, Johansen C, Joly F, Jordan K, Koczwara B, Lagergren P, Lambertini M, Lenihan D, Linardou H, Loprinzi C, Partridge A, Rauh S, Steindorf K, van der Graaf W, van de Poll-Franse L, Pentheroudakis G, Peters S, Pravettoni G. Annals of Oncology. 2022 Nov;33(11):1119-1133. doi: 10.1016/j.annonc.2022.07.1941. PMID: 35963481

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, Italiano A, Lindberg J, Merker JD, Montagut C, Normanno N, Pantel K, Pentheroudakis G, Popat S, Reis-Filho JS, Tie J, Seoane J, Tarazona N, Yoshino T, Turner NC. Annals of Oncology. 2022 Aug;33(8):750-768. doi: 10.1016/j.annonc.2022.05.520. PMID: 35809752

Evaluation of antineoplastic delayed-type hypersensitivity skin reactions in vitro. Roger I, Montero P, Garcia A, Milara J, Ribera P, Perez-Fidalgo JA, Cortijo J. Pharmaceuticals. 2022 Sep 6;15(9):1111. doi: 10.3390/ph15091111. PMID: 36145332

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. Italiano A, Cassier PA, Lin C, Alanko T, Peltola KJ, Gazzah A, Shiah HS, Calvo E, Cervantes A, Roda D, Tosi D, Gao B, Millward M, Warburton L, Tanner M, Englert S, Lambert S, Parikh A, Afar DE, Vosganian G, Moreno V. Cancer Immunology Immunotherapy. 2022 Feb;71(2):417-431. doi: 10.1007/s00262-021-02973-w. PMID: 34216247

First-in-human phase I Study of the OX40 agonist MOXR0916 in patients with advanced solid tumors. Kim T, Burris H, de Miguel Luken M, Pishvaian M, Bang Y, Gordon M, Awada A, Camidge D, Hodi F, McArthur G, Miller W, Cervantes A, Chow L, Lesokhin A, Rutten A, Sznol M, Rishipathak D, Chen S, Stefanich E, Pourmohamad T, Anderson M, Kim J, Huseni M, Rhee I, Siu L. Clinical Cancer Research. 2022 Aug 15;28(16):3452-3463. doi: 10.1158/1078-0432.CCR-21-4020. PMID: 35699599

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Felip E, Moreno V, Morgensztern D, Curigliano G, Rutkowski P, Trigo JM, Calvo A, Kowalski D, Cortinovis D, Plummer R, Maio M, Ascierto PA, Vladimirov VI, Cervantes A, Zudaire E, Hazra A, T’jollyn H, Bandyopadhyay N, Greger JG, Attiyeh E, Xie H, Calvo E. Cancer Chemotherapy and Pharmacology. 2022 Apr;89(4):499-514. doi: 10.1007/s00280-022-04414-6. PMID: 35298698

Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, Vogel A, Smyth E. Annals of Oncology. 2022 Oct;33(10):1005-1020. doi: 10.1016/j.annonc.2022.07.004. PMID: 35914639

Impact of the COVID-19 pandemic on a cancer fast-track programme. Martinez M, Moragon S, Ortega-Morillo B, Monton-Bueno J, Simon S, Rosello S, Insa A, Viala A, Navarro J, Sanmartin A, Fluixa C, Julve A, Soriano D, Buch E, Pena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner M, Cano A, Silvestre A, Teruel A, Bermejo B, Cervantes A, Chirivella Gonzalez I. Cancer Control. 2022 Jan-Dec;29:10732748221131000. doi: 10.1177/10732748221131000. PMID: 36355430

In the literature: April 2022. Ciardiello D, Roda D, Gambardella V, Cervantes A. ESMO Open. 2022 Apr 23;7(3):100479. doi: 10.1016/j.esmoop.2022.100479. PMID: 35472677

In the literature: December 2021. Montagut C, Gambardella V, Cabeza-Segura M, Fleitas T, Cervantes A. ESMO Open. 2022 Feb;7(1):100352. doi: 10.1016/j.esmoop.2021.100352. PMID: 34920292

In the literature: February 2022. Gambardella V, Cejalvo JM, Gonzalez Barrallo I, Gimeno Valiente F, Cervantes A. ESMO open. 2022 Feb 23;7(2):100411. doi: 10.1016/j.esmoop.2022.100411. PMID: 35219243

In the literature: July 2022. Gambardella V, Martinelli E, Tarazona N, Cervantes A. ESMO Open. 2022 Aug;7(4):100556. doi: 10.1016/j.esmoop.2022.100556. PMID: 35961192

In the literature: November 2022. Gambardella V, Cejalvo J, Cervantes A. ESMO Open. 2022 Nov 17;7(6):100643. doi: 10.1016/j.esmoop.2022.100643. PMID: 36403559

Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma. Cabeza-Segura M, Gambardella V, Gimeno-Valiente F, Carbonell-Asins JA, Alarcon-Molero L, Gonzalez-Vilanova A, Zuniga-Trejos S, Rentero-Garrido P, Villagrasa R, Gil M, Dura A, Richart P, Alonso N, Huerta M, Rosello S, Roda D, Tarazona N, Martinez-Ciarpaglini C, Castillo J, Cervantes A, Fleitas T. British Journal of Cancer. 2022 Dec;127(12):2198-2206. doi: 10.1038/s41416-022-02005-z. PMID: 36253523

Minimal residual disease in gastroesophageal adenocarcinoma: thesearch for the invisible. Tarazona N, Gimeno-Valiente F, Cervantes A. ESMO Open. 2022 Aug;7(4):100547. doi: 10.1016/j.esmoop.2022.100547. PMID: 35849878

MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer. Ferri C, Di Biase A, Bocchetti M, Zappavigna S, Wagner S, Le Vu P, Luce A, Cossu A, Vadakekolathu J, Miles A, Boocock D, Robinson A, Schwerdtfeger M, Tirino V, Papaccio F, Caraglia M, Regad T, Desiderio V. Journal of Experimental & Clinical Cancer Research. 2022 Jan 11;41(1):20. doi: 10.1186/s13046-021-02233-w. PMID: 35016717

Novel therapies for cardiometabolic disease: recent findings in studies with hormone peptide-derived G protein coupled receptor agonists. Jimenez-Marti E, Hurtado-Genoves G, Aguilar-Ballester M, Martinez-Hervas S, Gonzalez-Navarro H. Nutrients. 2022 Sep 13;14(18):3775. doi: 10.3390/nu14183775. PMID: 36145148

Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Obermannova R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken N, Vogel A, Smyth E. Annals of Oncology. 2022 Oct;33(10):992-1004. doi: 10.1016/j.annonc.2022.07.003. PMID: 35914638

Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: is it cost-effective in Spain. Moya-Alarcon C, Gonzalez-Dominguez A, Ivanova-Markova Y, Gimeno-Ballester V, Barretina-Ginesta M, Perez-Fidalgo J, Redondo A. Gynecologic Oncology. 2022 Feb;164(2):406-414. doi: 10.1016/j.ygyno.2021.11.011. PMID: 34844775

Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). Provencio M, Serna-Blasco R, Nadal E, Insa A, Garcia-Campelo MR, Casal Rubio J, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeno J, Cobo M, Lopez Vivanco G, Del Barco E, Bernabe Caro R, Vinolas N, Barneto Aranda I, Viteri S, Pereira E, Royuela A, Calvo V, Martin-Lopez J, Garcia-Garcia F, Casarrubios M, Franco F, Sanchez-Herrero E, Massuti B, Cruz-Bermudez A, Romero A. Journal of Clinical Oncology. 2022 Sep 1;40(25):2924-2933. doi: 10.1200/JCO.21.02660. PMID: 35576508

Paclitaxel induces epidermal molecular changes and produces subclinical alterations in the skin of gynecological cancer patients. Montero P, Perez-Leal M, Perez-Fidalgo JA, Sanz C, Estornut C, Roger I, Milara J, Cervantes A, Cortijo J. Cancers. 2022 Feb 23;14(5):1146. doi: 10.3390/cancers14051146. PMID: 35267454

Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas. Wermke M, Felip E, Gambardella V, Kuboki Y, Morgensztern D, Hamed Z, Liu M, Studeny M, Owonikoko T. Future Oncology. 2022 Aug;18(24):2639-2649. doi: 10.2217/fon-2022-0196. PMID: 35815644

Prognostic value of IGF2 mRNA-Binding Protein 3 (IGF2BP3) intratumoral expression in melanoma patients at the time of diagnosis: comparative analysis of rt-qpcr versus immunohistochemistry. Sanchez-Sendra B, Perez-Deben S, Gonzalez-Munoz JF, Murgui A, Monteagudo C. Cancers. 2022 May 7;14(9):2319. doi: 10.3390/cancers14092319. PMID: 35565448

Prospective real-world gynaecological cancer clinical registry with associated biospecimens: a collaborative model to promote translational research between GEICO and the Spanish Biobank Network. Lopez-Guerrero J, Mendiola M, Perez-Fidalgo J, Romero I, Torres A, Recalde D, Molina E, Gomez-Raposo C, Levin A, Herrero A, Alarcon J, Esteban C, Marquina G, Rubio M, Guerra E, Sanchez-Lorenzo L, Galvez-Montosa F, de Juan A, Churruca C, Gallego A, Gonzalez-Martin A. Cancers. 2022 Apr 13;14(8):1965. doi: 10.3390/cancers14081965. PMID: 35454870

Quality of life in cancer survivorship: Sociodemographic and disease-related moderators. Andreu Y, Martinez P, Soto-Rubio A, Perez-Marin M, Cervantes A, Arribas L. European Journal of Cancer Care. 2022 Nov;31(6):e13692. doi: 10.1111/ecc.13692. PMID: 36069249

RUNAT-BI: A Ruthenium(III) Complex as a Selective Anti-Tumor Drug Candidate against Highly Aggressive Cancer Cell Lines. Albanell-Fernandez M, Oltra S, Orts-Arroyo M, Ibarrola-Villava M, Carrasco F, Jimenez-Marti E, Cervantes A, Castro I, Martinez-Lillo J, Ribas G. Cancers. 2022 Dec 22;15(1):69. doi: 10.3390/cancers15010069. PMID: 36612065

Safety and efficacy of dostarlimab in patients with recurrent/advanced non-small cell lung cancer: results from cohort e of the Phase I GARNET Trial. Moreno V, Roda D, Pikiel J, Trigo J, Bosch-Barrera J, Drew Y, Kristeleit R, Hiret S, Bajor DL, Cruz P, Beck JT, Ghosh S, Dabrowski C, Antony G, Duan T, Veneris J, Zografos E, Subramanian J. Clinical Lung Cancer. 2022 Nov;23(7):e415-e427. doi: 10.1016/j.cllc.2022.05.013. PMID: 35729005

SARS-CoV-2 adaptive immunity in nursing home residents following a third dose of the Comirnaty COVID-19 vaccine. Gimenez E, Albert E, Zulaica J, Torres I, Rusu L, Rodriguez Moreno A, Burgos JS, Peiro S, Salas D, Vanaclocha H, Limon R, Alcaraz MJ, Sanchez-Paya J, Diez-Domingo J, Comas I, Gonzales Candelas F, Geller R, Navarro D. Clinical Infectious Diseases. 2022 Aug 24;75(1):e865-e868. doi: 10.1093/cid/ciac223. PMID: 35314856

SEOM-GEICO clinical guidelines on endometrial cancer (2021). Barretina Ginesta MP, Quindos M, Alarcon JD, Esteban C, Gaba L, Gomez C, Perez Fidalgo JA, Romero I, Santaballa A, Rubio Perez MJ. Clinical & Translational Oncology. 2022 Apr;24(4):625-634. doi: 10.1007/s12094-022-02799-7. PMID: 35312947

SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021) (vol 24, pg 646, 2022). Capdevila J, Gomez M, Guillot M, Paez D, Pericay C, Safont M, Tarazona N, Vera R, Vidal J, Sastre J. Clinical & Translational Oncology. 2022 Jul;24(7):1443-1444. doi: 10.1007/s12094-022-02855-2. PMID: 35596046

SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021). Capdevila J, Gomez MA, Guillot M, Paez D, Pericay C, Safont MJ, Tarazona N, Vera R, Vidal J, Sastre J. Clinical & Translational Oncology. 2022 Apr;24(4):646-657. doi: 10.1007/s12094-022-02816-9. PMID: 35303269

Short-term outcomes of colorectal cancer surgery in older patients: a novel nomogram predicting postoperative morbi-mortality. Moro-Valdezate D, Martin-Arevalo J, Ferro-Echevarria O, Pla-Marti V, Garcia-Botello S, Perez-Santiago L, Gadea-Mateo R, Tarazona N, Roda D, Rosello-Keranen S, Espi-Macias A. Langenbeck’s Archives of Surgery. 2022 Dec;407(8):3587-3597. doi: 10.1007/s00423-022-02688-1. PMID: 36129528

SMG8/SMG9 heterodimer loss modulates SMG1 kinase to drive ATR inhibitor resistance. Llorca-Cardenosa MJ, Aronson LI, Krastev DB, Nieminuszczy J, Alexander J, Song F, Dylewska M, Broderick R, Brough R, Zimmermann A, Zenke FT, Gurel B, Riisnaes R, Ferreira A, Roumeliotis T, Choudhary J, Pettitt SJ, de Bono J, Cervantes A, Haider S, Niedzwiedz W, Lord CJ, Chong IY. Cancer Research. 2022 Nov 2;82(21):3962-3973. doi: 10.1158/0008-5472.CAN-21-4339. PMID: 36273494

SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA. Prat A, Paz-Ares L, Juan M, Felip E, Garralda E, Gonzalez B, Arance A, Martin-Liberal J, Gavila J, Lopez-Gonzalez A, Miguel Cejalvo J, Izarzugaza Y, Amillano K, Garcia Corbacho J, Saura C, Racca F, Hierro C, Sanfeliu E, Gonzalez X, Canes J, Villacampa G, Salvador F, Pascual T, Mesia R, Cervantes A, Tabernero J. Future Oncology. 2022 Oct 6. doi: 10.2217/fon-2022-0660. PMID: 36200668

Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+breast tumors. Rivas EI, Linares J, Zwick M, Gomez-Llonin A, Guiu M, Labernadie A, Badia-Ramentol J, Llado A, Bardia L, Perez-Nunez I, Martinez-Ciarpaglini C, Tarazona N, Sallent-Aragay A, Garrido M, Celia-Terrassa T, Burgues O, Gomis RR, Albanell J, Calon A. Nature Communications. 2022 Sep 9;13(1):5310. doi: 10.1038/s41467-022-32782-3. PMID: 36085201

The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally. Van Schooten T, Derks S, Jimenez-Marti E, Carneiro F, Figueiredo C, Ruiz E, Alsina M, Molero C, Garrido M, Riquelme A, Caballero C, Lezcano E, O’Connor J, Esteso F, Farres J, Mas J, Lordick F, Vogt J, Cardone A, Girvalaki C, Cervantes A, Fleitas T. BMC Cancer. 2022 Jun 13;22(1):646. doi: 10.1186/s12885-022-09689-9. PMID: 35692051

The prognostic value of miR-125b, miR-200c and miR-205 in primary cutaneous malignant melanoma is independent of BRAF mutational status. Sanchez-Sendra B, Gonzalez-Munoz J, Perez-Deben S, Monteagudo C. Cancers. 2022 Mar 16;14(6):1532. doi: 10.3390/cancers14061532. PMID: 35326682

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy. Casarrubios M, Provencio M, Nadal E, Insa A, Garcia-Campelo MR, Lazaro-Quintela M, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeno J, Cobo M, Lopez Vivanco G, Del Barco E, Bernabe R, Vinolas N, Barneto Aranda I, Massuti B, Sierra-Rodero B, Martinez-Toledo C, Fernandez-Miranda I, Serna-Blanco R, Romero A, Calvo V, Cruz-Bermudez A. Journal for Immunotherapy of Cancer. 2022 Sep;10(9):e005320. doi: 10.1136/jitc-2022-005320. PMID: 36171009

Veliparib plus carboplatin and paclitaxel versus investigator’s choice of standard chemotherapy in patients with advanced non-squamous non-small cell lung cancer. Govindan R, Lind M, Insa A, Khan SA, Uskov D, Tafreshi A, Guclu S, Bar J, Kato T, Lee KH, Nakagawa K, Hansen O, Biesma B, Kundu MG, Dunbar M, He L, Ansell P, Sehgal V, Huang X, Glasgow J, Bach BA. Clinical Lung Cancer. 2022 May;23(3):214-225. doi: 10.1016/j.cllc.2022.01.005. PMID: 35331641

Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?. Insa A, Martin-Martorell P, Di Liello R, Fasano M, Martini G, Napolitano S, Vicidomini G, Cappabianca S, Franco R, Morgillo F, Della Corte CM. Critical Reviews in Oncology/Hematology. 2022 Jan;169:103538. doi: 10.1016/j.critrevonc.2021.103538. PMID: 34801700

Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. Smyth EC, Gambardella V, Cervantes A, Fleitas T. Annals of Oncology. 2021 May;32(5):590-599. doi: 10.1016/j.annonc.2021.02.004. Epub 2021 Feb 17. PMID: 33609722

Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Huerta M, Rosello S, Sabater L, Ferrer A, Tarazona N, Roda D, Gambardella V, Alfaro-Cervello C, Garces-Albir M, Cervantes A, Ibarrola-Villava M. Cancers. 2021 Feb 27;13(5):994. doi: 10.3390/cancers13050994. PMID: 33673558

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. Sierra-Rodero B, Cruz-Bermudez A, Nadal E, Garitaonaindia Y, Insa A, Mosquera J, Casal-Rubio J, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeno J, Cobo M, Lopez Vivanco G, Del Barco E, Bernabe Caro R, Vinolas N, Barneto Aranda I, Viteri S, Massuti B, Laza-Briviesca R, Casarrubios M, Garcia-Grande A, Romero A, Franco F, Provencio M. Journal for ImmunoTherapy of Cancer. 2021 Aug;9(8):e002804. doi: 10.1136/jitc-2021-002804. PMID: 34446577

Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. Lambertini M, Ceppi M, Hamy A, Caron O, Poorvu P, Carrasco E, Grinshpun A, Punie K, Rousset-Jablonski C, Ferrari A, Paluch-Shimon S, Toss A, Senechal C, Puglisi F, Pogoda K, Perez-Fidalgo J, De Marchis L, Ponzone R, Livraghi L, Estevez-Diz M, Villarreal-Garza C, Dieci M, Clatot F, Duhoux F, Graffeo R, Teixeira L, Cordoba O, Sonnenblick A, Ferreira A, Partridge A, Di Meglio A, Saule C, Peccatori F, Bruzzone M, t’Kint de Roodenbeke M, Ameye L, Balmana J, Del Mastro L, Azim H. NPJ breast cancer. 2021 Feb 12;7(1):16. doi: 10.1038/s41523-021-00224-w. PMID: 33579978

Clinical Case Presentation and Discussion During ESO-ESMO Masterclass: a 10-Year Interactive Educational Experience. Pavlidis N, Peccatori F, Aapro M, Cervantes Ruiperez A, Stahel R, Eniu A, Cavalli F, Costa A. Journal of Cancer Education. 2021 Oct;36(5):1124-1128. doi: 10.1007/s13187-020-01744-y. PMID: 32303982

Clinicians’ attitude to doublet plus Anti-EGFR versus triplet plus bevacizumab as first-line treatment in left-sided RAS and BRAF wild-type metastatic colorectal cancer patients: a multicenter, “real-life”, case-control study. Parisi A, Porzio G, Cannita K, Venditti O, Avallone A, Filippi R, Salvatore L, Tortora G, Ribelli M, Nigro O, Gelsomino F, Spallanzani A, Zurlo V, Leo S, Dell’Aquila E, Claudia F, Lombardi P, Keranen S, Aimar G, Depetris I, Giampieri R, Morelli C, De Tursi M, Tinari N, Di Pietro F, De Galitiis F, Zanaletti N, Troiani T, Vitale P, Garajova I, Ghidini M, Spinelli G, Zoratto F, Roberto M, Ierino D, Petrillo A, D’Orazio C, Ficorella C, Cortellini A. Clinical Colorectal Cancer. 2021 Dec;20(4):318-325. doi: 10.1016/j.clcc.2021.07.003. PMID: 34380594

Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial. Romero A, Jantus-Lewintre E, Garcia-Pelaez B, Royuela A, Insa A, Cruz P, Collazo A, Altozano J, Vidal O, Diz P, Cobo M, Hernandez B, Estevez S, Benitez G, Guirado M, Majem M, Bernabe R, Ortega A, Blasco A, Bosch-Barrera J, Jurado J, Gonzalez J, Viteri S, Giron C, Massuti B, Martin A, Rodriguez-Festa A, Calabuig-Farinas S, Molina-Vila M, Provencio M. Molecular Oncology. 2021 Jan;15(1):43-56. doi: 10.1002/1878-0261.12832. PMID: 33107189

Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Gambardella V, Martinez-Ciarpaglini C, Fleitas T, Cervantes A. ESMO Open. 2021 Nov 6;6(6):100285. doi: 10.1016/j.esmoop.2021.100285. PMID: 34752996

Cutaneous lymphadenoma is a distinct trichoblastoma-like lymphoepithelial tumor with diffuse androgen receptor immunoreactivity, notch1 ligand in reed-sternberg-like cells, and common EGFR somatic mutations. Monteagudo C, Funez R, Sanchez-Sendra B, Gonzalez-Munoz JF, Nieto G, Alfaro-Cervello C, Murgui A, Barr R. The American Journal of Surgical Pathology. 2021 Oct 1;45(10):1382-1390. doi: 10.1097/PAS.0000000000001727. PMID: 34232601

Digital pathology: accurate technique for quantitative assessment of histological features in metabolic-associated fatty liver disease. Marti-Aguado D, Rodriguez-Ortega A, Mestre-Alagarda C, Bauza M, Valero-Perez E, Alfaro-Cervello C, Benlloch S, Perez-Rojas J, Ferrandez A, Alemany-Monraval P, Escudero-Garcia D, Monton C, Aguilera V, Alberich-Bayarri A, Serra M, Marti-Bonmati L. Alimentary Pharmacology & Therapeutics. 2021 Jan;53(1):160-171. doi: 10.1111/apt.16100. PMID: 32981113

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer. Kaminska K, Akrap N, Staaf J, Alves C, Ehinger A, Ebbesson A, Hedenfalk I, Beumers L, Veerla S, Harbst K, Ehmsen S, Borgquist S, Borg A, Perez-Fidalgo A, Ditzel H, Bosch A, Honeth G. Breast Cancer Research. 2021 Feb 18;23(1):26. doi: 10.1186/s13058-021-01402-1. PMID: 33602273

Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. Riudavets M, Bosch-Barrera J, Cabezon-Gutierrez L, Tain P, Hernandez A, Alonso M, Blanco R, Galvez E, Insa A, Mielgo X, Moran T, Ponce S, Roa D, Sanchez J, Majem M. Clinical & Translational Oncology. 2021 Dec;23(12):2560-2567. doi: 10.1007/s12094-021-02661-2. PMID: 34292495

Epigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer. Gimeno-Valiente F, Riffo-Campos A, Torres L, Tarazona N, Gambardella V, Cervantes A, Lopez-Rodas G, Franco L, Castillo J. Cancers. 2021 Mar 21;13(6):1433. doi: 10.3390/cancers13061433. PMID: 33801071

ESMO pays tribute to Professor Jose Baselga. Peters S, Tabernero J, Cervantes A, Banerjee S, Giuliani R, Lordick F. Annals of Oncology. 2021 Jul;32(7):823-824. doi: 10.1016/j.annonc.2021.04.001. PMID: 34090547

ESMO pays tribute to Professor Jose Baselga. Peters S, Tabernero J, Cervantes A, Banerjee S, Giuliani R, Lordick F. ESMO open. 2021 Jul;32(7):823-824. doi: 10.1016/j.annonc.2021.04.001. PMID: 34144776

ESO-ESMO Masterclass in Clinical Oncology: Analysis and Evaluation of the Learning Self-Assessment Test. Pavlidis N, Peccatori F, Aapro M, Eniu A, Stahel R, Cervantes A, Cavalli F, Costa A. Journal of Cancer Education. 2021 Jun;36(3):556-560. doi: 10.1007/s13187-019-01664-6. PMID: 31845109

First-in-human phase I study of a next-generation, oral, transforming growth factor-beta receptor 1 inhibitor, LY3200882 in patients with advanced cancer. Yap TA, Vieito M, Baldini C, Sepulveda-Sanchez JM, Kondo S, Simonelli M, Cosman R, van der Westhuizen A, Atkinson V, Carpentier AF, Lohr M, Redman R, Mason W, Cervantes A, Le Rhun E, Ochsenreither S, Warren L, Zhao Y, Callies S, Estrem ST, Man M, Gandhi L, Avsar E, Melisi D. Clinical Cancer Research. 2021 Dec 15;27(24):6666-6676. doi: 10.1158/1078-0432.CCR-21-1504. PMID: 34548321

First-line biological agents plus chemotherapy in older patients with metastatic colorectal cancer: a retrospective pooled analysis. Garcia-Alfonso P, Diaz-Rubio E, Abad A, Carrato A, Massuti B, Ortiz-Morales M, Mozo J, Munoz A, Duran G, Sastre J, Safont M, Ferreiro R, Rivera F, Gonzalez E, Valladares-Ayerbes M, Gravalos C, Alonso-Orduna V, Vieitez J, Yubero A, Aranda E, Spanish Cooperative Grp Treatment. Drugs & Aging. 2021 Mar;38(3):219-231. doi: 10.1007/s40266-021-00834-w. PMID: 33615402

Folliculotropic mycosis fungoides with flexural eruptive cysts and comedones in a 14-year-old boy. Roca-Gines J, Alfaro-Cervello C, Sanchez-Arraez J, Torres-Navarro I, Navarro-Mira MA, Monteagudo C, Botella-Estrada R. American Journal of Dermatopathology. 2021 Sep 1;43(9):656-658. doi: 10.1097/DAD.0000000000001958. PMID: 33989213

Gonzales J,Hernández J,Wilson TC,Adilbay D,Cornejo M,Franca PDD,Guru N,Schroeder CI,King GF,Lewis JS,Reiner T. Bimodal Imaging of Mouse Peripheral Nerves with Chlorin Tracers. Mol. Pharm. 2021. 18. (3):p. 940-951. IF:5,364. (1).

Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Bertocchi A, Carloni S, Ravenda PS, Bertalot G, Spadoni I, Lo Cascio A, Gandini S, Lizier M, Braga D, Asnicar F, Segata N, Klaver C, Brescia P, Rossi E, Anselmo A, Guglietta S, Maroli A, Spaggiari P, Tarazona N, Cervantes A, Marsoni S, Lazzari L, Jodice M, Giovanna L, Chiara E, Marco PS, Di Fiore PP, Viale G, Spinelli A, Pozzi C, Penna G, Rescigno M. Cancer Cell. 2021 May 10;39(5):708-724.e11. doi: 10.1016/j.ccell.2021.03.004. PMID: 33798472

Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM). Jimenez-Labaig P, Pacheco-Barcia V, Cebria A, Galvez F, Obispo B, Paez D, Quilez A, Quintanar T, Ramchandani A, Remon J, Rogado J, Sanchez D, Sanchez-Canovas M, Sanz-Garcia E, Sesma A, Tarazona N, Cotes A, Gonzalez E, Bosch-Barrera J, Fernandez A, Felip E, Vera R, Rodriguez-Lescure A, Elez E. ESMO Open. 2021 Jul 26;6(4):100215. doi: 10.1016/j.esmoop.2021.100215. PMID: 34325108

In the literature: April 2021. Martin-Martorell P, Gonzalez-Barrallo I, Gambardella V, Cejalvo J M, Cervantes A. ESMO open. 2021 Apr 19;6(3):100116. doi: 10.1016/j.esmoop.2021.100116. PMID: 33887688

In the literature: August 2021. Gambardella V, Alfaro-Cervello C, Cejalvo J, Tapia M, Cervantes A. ESMO Open. 2021 Aug 16;6(5):100247. doi: 10.1016/j.esmoop.2021.100247. PMID: 34411970

In the literature: December 2020. Gambardella V, Ibarrola-Villaba M, Tarazona N, Cervantes A. ESMO Open. 2021 Jan 4;6(1):100009. doi: 10.1016/j.esmoop.2020.100009. PMID: 33399075

In the literature: February 2021. Cejalvo J, Gambardella V, Fleitas T, Cervantes A. ESMO Open. 2021 Feb 24;6(2):100061. doi: 10.1016/j.esmoop.2021.100061. PMID: 33639602

In the literature: June 2021. Gambardella V, Candia L, Tapia M, Cejalvo JM, Cervantes A. ESMO open. 2021 Jun;6(3):100186. doi: 10.1016/j.esmoop.2021.100186. PMID: 34098228

LungBEAM: a prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Garrido P, Paz-Ares L, Majem M, Moran T, Trigo JM, Bosch-Barrera J, Garcia-Campelo R, Gonzalez-Larriba JL, Sanchez-Torres JMiguel, Isla D, Vinolas N, Camps C, Insa A, Juan O, Massuti B, Paredes A, Artal A, Lopez-Brea M, Palacios J, Felip E. Cancer Medicine. 2021 Sep;10(17):5878-5888. doi: 10.1002/cam4.4135.PMID: 34296539

Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. Gambardella V, Lombardi P, Carbonell-Asins JA, Tarazona N, Cejalvo JM, Gonzalez-Barrallo I, Martin-Arana J, Tebar-Martinez R, Viala A, Bruixola G, Hernando C, Blasco I, Papaccio F, Martinez-Ciarpaglini C, Alfaro-Cervello C, Seda-Garcia E, Blesa S, Chirivella I, Castillo J, Monton-Bueno JV, Rosello S, Huerta M, Perez-Fidalgo A, Martin-Martorell P, Insa-Molla A, Fleitas T, Rentero-Garrido P, Zuniga-Trejos S, Cervantes A, Roda D. British Journal of Cancer. 2021 Oct;125(9):1261-1269. doi: 10.1038/s41416-021-01502-x. PMID: 34493820

Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phaseII trial (ROLANDO study). Perez-Fidalgo J, Cortes A, Guerra E, Garcia Y, Iglesias M, Bohn Sarmiento U, Calvo Garcia E, Manso Sanchez L, Santaballa A, Oaknin A, Redondo A, Rubio M, Gonzalez-Martin A. ESMO Open. 2021 Jul 27;6(4):100212. doi: 10.1016/j.esmoop.2021.100212. PMID: 34329939

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Yoshino T, Argiles G, Oki E, Martinelli E, Taniguchi H, Arnold D, Mishima S, Li Y, Smruti B, Ahn J, Faud I, Chee C, Yeh K, Lin P, Chua C, Hasbullah H, Lee M, Sharma A, Sun Y, Curigliano G, Bando H, Lordick F, Yamanaka T, Tabernero J, Baba E, Cervantes A, Ohtsu A, Peters S, Ishioka C, Pentheroudakis G. Annals of Oncology. 2021 Dec;32(12):1496-1510. doi: 10.1016/j.annonc.2021.08.1752. PMID: 34411693

Peritoneal invasion and metachronous peritoneal metastases after colon cancer surgery: The role of homogeneous, reliable assessment and confounders. Pellino G, Garcia-Granero E, Cervantes A. European Journal of Surgical Oncology. 2021 Oct;47(10):2697. doi: 10.1016/j.ejso.2021.06.031. PMID: 34217579

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers. Jhaveri K, Chang M, Juric D, Saura C, Gambardella V, Melnyk A, Patel M, Ribrag V, Ma C, Aljumaily R, Bedard P, Sachdev J, Dunn L, Won H, Bond J, Jones S, Savage H, Scaltriti M, Wilson T, Wei M, Hyman D. Clinical Cancer Research. 2021 Jan 15;27(2):447-459. doi: 10.1158/1078-0432.CCR-20-2657. PMID: 33148674

Post-induction management in patients with left-sided RAS and BRAF wild-type metastatic colorectal cancer treated with first-line anti-egfr-based doublet regimens: a multicentre study. Parisi A, Cortellini A, Venditti O, Filippi R, Salvatore L, Tortora G, Ghidini M, Nigro O, Gelsomino F, Zurlo IV, Fulgenzi C, Lombardi P, Roselló Keränen S, Depetris I, Giampieri R, Morelli C, Di Marino P, Di Pietro FR, Zanaletti N, Vitale P, Garajova I, Spinelli GP, Zoratto F, Roberto M, Petrillo A, Aimar G, Patruno L, D’Orazio C, Ficorella C, Ferri C, Porzio G. Frontiers in Oncology. 2021 Oct 27;11:712053. doi: 10.3389/fonc.2021.712053. PMID: 34778029

Postoperative ctDNA monitoring: a canary in a coalmine. Lumish M, Tarazona N, Janjigian Y. Annals of oncology. 2021 Apr;32(4):431-433. doi: 10.1016/j.annonc.2021.01.005. PMID: 33484835

Potential biomarkers associated with multiple sclerosis pathology. Mathur D, Mishra BK, Rout S, Lopez-Iranzo FJ, Lopez-Rodas G, Vallamkondu J, Kandimalla R, Casanova B. International Journal of Molecular Sciences. 2021 Sep 25;22(19):10323. doi: 10.3390/ijms221910323. PMID: 34638664

Pre-treatment tissue TCR repertoire evenness is associated with complete pathological response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy. Casarrubios M, Cruz-Bermudez A, Nadal E, Insa A, Garcia-Campelo R, Lazaro M, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, de Castro-Carpeno J, Cobo M, Lopez-Vivanco G, Del Barco E, Bernabe Caro R, Vinolas N, Barneto Aranda I, Viteri S, Massuti B, Barquin M, Laza-Briviesca R, Sierra-Rodero B, Parra E, Sanchez-Espiridion B, Rocha P, Kadara H, Wistuba I, Romero A, Calvo V, Provencio M. Clinical Cancer Research. 2021 Nov 1;27(21):5878-5890. doi: 10.1158/1078-0432.CCR-21-1200. PMID: 34376534

Prognostic implications of surgical specimen quality on the oncological outcomes of open and laparoscopic surgery in mid and low rectal cancer. Pla-Marti V, Martin-Arevalo J, Moro-Valdezate D, Garcia-Botello S, Perez-Santiago L, Lapena-Rodriguez M, Bauza-Collado M, Huerta M, Rosello-Keranen S, Espi-Macias A. Langenbeck’s archives of surgery. 2021 Dec;406(8):2759-2767. doi: 10.1007/s00423-021-02351-1. PMID: 34716825

Radiomics and radiogenomics in head and neck squamous cell carcinoma: potential contribution to patient management and challenges. Bruixola G, Remacha E, Jimenez-Pastor A, Dualde D, Viala A, Monton J, Ibarrola-Villava M, Alberich-Bayarri A, Cervantes A. Cancer Treatment Reviews. 2021 Sep;99:102263. doi: 10.1016/j.ctrv.2021.102263. PMID: 34343892

Reply to the letter to the editor: adjuvant nivolumab for the management of the pathological residual disease in esophageal or junctional tumors: a word of caution by P.K. Garg, R. Kumar and P. Dixit. Smyth EC, Gambardella V, Cervantes A, Fleitas T. Annals of Oncology. 2021 Sep;32(9):1190-1191. doi: 10.1016/j.annonc.2021.05.795. PMID: 34033882

Retrospective study of regorafenib versus TAS-102 efficacy and safety in chemorefractory Metastatic Colorectal Cancer (mCRC) patients: a multi-institution real life clinical data. Vitale P, Zanaletti N, Famiglietti V, De Falco V, Cervantes A, Rosellò S, Fenocchio E, Milanesio M, Lombardi P, Ciardiello D, Martini G, Martinelli E, Ciardiello F, Troiani T, Napolitano S. Clinical Colorectal Cancer. 2021 Sep;20(3):227-235. doi: 10.1016/j.clcc.2021.06.002. PMID: 34226142

Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer. Condorelli M, Bruzzone M, Ceppi M, Ferrari A, Grinshpun A, Hamy AS, de Azambuja E, Carrasco E, Peccatori FA, Di Meglio A, Paluch-Shimon S, Poorvu PD, Venturelli M, Rousset-Jablonski C, Senechal C, Livraghi L, Ponzone R, De Marchis L, Pogoda K, Sonnenblick A, Villarreal-Garza C, Cordoba O, Teixeira L, Clatot F, Punie K, Graffeo R, Dieci MV, Perez-Fidalgo JA, Duhoux FP, Puglisi F, Ferreira AR, Blondeaux E, Peretz-Yablonski T, Caron O, Saule C, Ameye L, Balmana J, Partridge AH, Azim HA, Demeestere I, Lambertini M. ESMO Open. 2021 Nov 11;6(6):100300. doi: 10.1016/j.esmoop.2021.100300. PMID: 34775302

SEOM clinical guideline in ovarian cancer (2020). Redondo A, Guerra E, Manso L, Martin-Lorente C, Martinez-Garcia J, Perez-Fidalgo J, Varela M, Rubio M, Barretina-Ginesta M, Gonzalez-Martin A. Clinical & translational oncology. 2021 May;23(5):961-968. doi: 10.1007/s12094-020-02545-x. PMID: 33515422

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Bahadoer R, Dijkstra E, van Etten B, Marijnen C, Putter H, Kranenbarg E, Roodvoets A, Nagtegaal I, Beets-Tan R, Blomqvist L, Fokstuen T, Ten Tije A, Capdevila J, Hendriks M, Edhemovic I, Cervantes A, Nilsson P, Glimelius B, van de Velde C, Hospers G, RAPIDO collaborative investigators. Lancet. Oncology. 2021 Jan;22(1):29-42. doi: 10.1016/S1470-2045(20)30555-6. PMID: 33301740

Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib. Malhi V, Budha N, Sane R, Huang J, Liederer B, Meng R, Patel P, Deng Y, Cervantes A, Tabernero J, Musib L. Cancer Chemotherapy and Pharmacology. 2021 Dec;88(6):921-930. doi: 10.1007/s00280-021-04344-9. PMID: 34471960

Teh JH,Braga M,Allott L,Barnes C,Hernandez J,Tang MX,Aboagye EO,Long N. A kit-based aluminium-[¹⁸F]fluoride approach to radiolabelled microbubbles. Chem. Commun. 2021. 57. (88):p. 11677-11680. IF:6,065. (2).

Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation. Martinez MT, Monton-Bueno J, Simon S, Ortega B, Moragon S, Rosello S, Insa A, Navarro J, Sanmartin A, Julve A, Buch E, Pena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner MJ, Cano A, Silvestre A, Teruel A, Lluch A, Cervantes A, Chirivella Gonzalez I. ESMO open. 2021 May 11;6(3):100148. doi: 10.1016/j.esmoop.2021.100148. PMID: 33989988

The COVID-19 pandemic could be a setback for gender equality in oncology-and a key moment to push ahead with transformative policies. Cervantes A. ESMO Open. 2021 Jun;6(3):100169. doi: 10.1016/j.esmoop.2021.100169. PMID: 34144777

Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national registry on behalf of the Spanish Rectal Cancer Project. Pellino G, Alós R, Biondo S, Codina-Cazador A, Enríquez-Navascues J, Espín-Basany E, Roig-Vila J, Cervantes Ruiperez A, Carceller R, Spanish Rectal Cancer Project collaborators. EJSO. 2021 Feb;47(2):276-284. doi: 10.1016/j.ejso.2020.04.056. PMID: 32950316

Unexpected finding of iIntravascular large B-cell lymphoma by a skin biopsy. Guillen-Climent S, Garcia-Vazquez A, Martinez-Ciarpaglini C. Medicina Clinica. 2021 Aug 13;157(3):151-152. doi: 10.1016/j.medcli.2020.04.051. PMID: 32951879

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Vogel A, Martinelli E, ESMO Guidelines Commite. Annals of Oncology. 2021 Jun;32(6):801-805. doi: 10.1016/j.annonc.2021.02.014. PMID: 33716105

Using DNA sequencing data to quantify T cell fraction and therapy response. Bentham R, Litchfield K, Watkins T, Lim E, Rosenthal R, Martinez-Ruiz C, Hiley C, Al Bakir M, Salgado R, Moore D, Jamal-Hanjani M, Swanton C, McGranahan N, TRACERx Consortium. Nature. 2021 Sep;597(7877):555-560. doi: 10.1038/s41586-021-03894-5. PMID: 34497419